Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
Status:
Not yet recruiting
Trial end date:
2024-08-18
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the
understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the
metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor
and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future
studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed
xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug
substrates.